SPRO Spero Therapeutics, Inc.

$1.13▲ +0.89% Healthcare Other
After hours $1.14▲ +0.88% Sep 11, 7:30 PM ET
Volume 308.6K Avg Volume (10D) 358.4K
Key Metrics & Fundamentals
Market Cap
$65.81M
P/E Ratio
8.1
Div Yield
–%
52W Range
1.08 - 3.08
% vs 50 MA
-18.28%
% vs 200 MA
-48.45%
RSI-14
31.0
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.49
Free Cash Flow
-$5.36M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$9.93M
COGS
–
Operating Exp
$9.93M
Operating Income
-$9.93M
EBIT
-$9.93M
Pretax Income
-$9.55M
Net Income
-$9.55M
EPS (Diluted)
-0.16
Price & Volume History
Loading chart…
Recent News
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 8:05 PM
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 2, 2026 8:01 PM
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 19, 2026 9:28 PM
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 13, 2026 12:30 PM
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
GuruFocus.com · Aug 13, 2026 5:01 AM
Spero Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 13, 2026 2:04 AM
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
GlobeNewswire · Aug 12, 2026 8:01 PM
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
GlobeNewswire · Aug 4, 2026 8:01 PM
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire · Jul 27, 2026 12:00 PM
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Hospital Management · Jul 15, 2026 10:01 AM
Financial Overview - Income Statement Quarterly

See SPRO's money flow as a full page

Social Sentiment
Avg +0.90 · 1 posts
NewsDiscussionPriceTargetSpero Therapeutics is one of the strangest situations I’ve ever come across in biotech
r/stocks · Jun 5, 2026
The post is entirely centered around Spero’s prospects and the FDA ruling.
very_positive +0.90
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙